ClinicalTrials.gg
Active, not recruitingNCT05631093Updated Nov 21, 2025Results posted

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

A Phase 3 interventional study of ART and DOR/ISL in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Active, not recruiting at 53 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
553
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the antiretroviral activity of a switch to DOR/ISL compared with continued baseline ART at Week 48. The primary hypothesis is that DOR/ISL is non-inferior to continued baseline ART, as assessed by the percentage of participants with HIV-1 ribonucleic acid (RNA) ≥50 copies/mL at Week 48, with a margin of 4 percentage points used to define non-inferiority.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 (HIV-1) positive with plasma HIV-1 Ribonucleic Acid (RNA) \<50 copies/mL at screening
  • Has been receiving continuous, stable oral 2-drug or 3-drug combination (± PK booster) antiretroviral therapy ART with documented viral suppression (HIV-1 RNA \<50 copies/mL) for ≥3 consecutive months prior to providing documented and has no history of prior virologic treatment failure on any past or current regimen
  • Female is not a participant of (POCBP); or if a POCBP uses an acceptable method or abstains from penile-vaginal intercourse as their preferred and usual lifestyle; has a negative highly sensitive pregnancy test; and whose medical history, menstrual history, and recent sexual activity has been reviewed by the investigator

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has a diagnosis of an active acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within 30 days prior to screening
  • Has active virus (HBV) infection
  • Has chronic virus (HCV) infection consistent with cirrhosis
  • Has a ≤5 years prior history of
  • Is taking or is anticipated to require systemic therapy, immune modulators, or strong and moderate cytochrome P450 3A () inducers
  • Has taken long-acting HIV therapy at any time
  • Is currently participating in or has participated in a clinical study and received (or is receiving) an compound or device from 45 days prior to Day 1 through the study treatment period
  • Has a documented or known virologic resistance to Doravine (DOR)
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
553 participants (actual)

Study arms

  • Experimental
    DOR/ISL

    Participants with Human Immunodeficiency Virus-1 (HIV-1) that have been virologically suppressed for ≥3 consecutive months who were previously treated with continuous baseline antiretroviral therapy (ART) receive doravine/islatravir (DOR/ISL), a fixed dose combination (FDC) of 100 mg DOR/0.25 mg ISL orally once daily (qd) for 144 weeks. At Week 144, participants who consent to enter the optional study extension will continue to receive DOR/ISL qd (100 mg/0.25 mg) for an additional 96 weeks or until it is commercially accessible (whichever comes first).

    Drug: DOR/ISL

  • Active comparator
    ART + DOR/ISL

    Participants with HIV-1 that has been virologically suppressed for ≥3 consecutive months who were previously treated with continuous baseline ART received standard of care (SOC) ART for 48 weeks, followed by treatment with DOR/ISL as a FDC of 100 mg DOR/0.25 mg ISL orally qd until Week 144. At Week 144, participants who consent to enter the optional study extension will continue to receive DOR/ISL qd (100 mg/0.25 mg) for an additional 96 weeks or until it is commercially accessible (whichever comes first).

    Drug: ART

Interventions

  • DrugART

    Standard of care ART, per approved product list, taken orally

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    Single tablet combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.

    Also known as: MK-8591A

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48

    HIV-1 RNA levels in plasma were measured by polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  2. Percentage of Participants With One or More Adverse Events (AEs) at Week 48

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 48 are reported.

    Time frame: Up to Week 48

  3. Percentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 48

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 48 are reported.

    Time frame: Up to Week 48

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 48

  3. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 96

  4. Participants With HIV-1 RNA <200 Copies/mL at Week 144

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 144

  5. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 144

  7. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 96

  8. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

    HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

    Time frame: Week 144

  9. Mean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 48

    Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The mean change of plasma CD4+ T-Cell count from baseline to Week 48 is presented.

    Time frame: Baseline at Day 1 and Week 48

  10. Mean Change of Plasma CD4+ T-Cell Count From Baseline Week 48 to Week 96

    Mean change from baseline at Week 48 in CD4+ T-cell count at Week 96. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.

    Time frame: Baseline at Week 48 and Week 96

  11. Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 48 to Week 144

    Mean change from baseline at Week 48 in CD4+ T-cell count at Week 144. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.

    Time frame: Baseline at Week 48 and Week 144

  12. Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 96

    Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.

    Time frame: Baseline at Day 1 and Week 96

  13. Mean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 144

    Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.

    Time frame: Baseline at Day 1 and Week 144

  14. Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48

    Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA \>=200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA \>=200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Participants with HIV-1 RNA \>=400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.

    Time frame: Up to Week 48

  15. Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48

    Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Low density lipoprotein cholesterol (LDL-C) at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.

    Time frame: Baseline and Week 48

  16. Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48

    Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Non-HDL-C at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.

    Time frame: Baseline and Week 48

  17. Participants With One or More AEs at Week 96

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 96 is reported.

    Time frame: Up to Week 96

  18. Participants With One or More AEs at Week 144

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 144 is reported.

    Time frame: Up to Week 144

  19. Percentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 96

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 96 are reported.

    Time frame: Up to Week 96

  20. Percentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 144

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 144 are reported.

    Time frame: Up to Week 144

  21. Percentage of Participants With One or More AEs From Week 48 up to Week 96

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 96 is reported.

    Time frame: Week 48 up to Week 96

  22. Percentage of Participants With One or More AEs From Week 48 up to Week 144

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 144 is presented.

    Time frame: Week 48 up to Week 144

  23. Percentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 96

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 96 are reported.

    Time frame: Week 48 up to Week 96

  24. Percentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 144

    An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 144 are reported.

    Time frame: Week 48 up to Week 144

07

Results

Posted Nov 21, 2025

Participant flow

Adults living with human immunodeficiency virus-1 (HIV-1) receiving baseline antiretroviral therapy (ART) were enrolled.

Participant flow — Overall Study
MilestoneDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Started368185
Treated366185
Completed93
Not completed359182
Withdrew: Death01
Withdrew: Lost to follow-up12
Withdrew: Physician decision10
Withdrew: Withdrawal by subject41
Withdrew: Ongoing353177
Withdrew: Adverse event01

Outcome measures

PrimaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48

HIV-1 RNA levels in plasma were measured by polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 48
Percentage of ParticipantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 481.44.9
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Miettinen and Nurminen · p = <0.001 · Estimated difference: -3.58 · 95% CI -7.81 to -0.77The Miettinen and Nurminen method was stratified by corrected baseline ART regimen with Cochran-Mantel-Haenszel (CMH) weights.
PrimaryPercentage of Participants With One or More Adverse Events (AEs) at Week 48

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 48 are reported.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With One or More Adverse Events (AEs) at Week 48
Percentage of ParticipantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With One or More Adverse Events (AEs) at Week 4879.583.8
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: -4.3 · 95% CI -10.7 to 2.8Difference in percentage versus (vs) Baseline ART was based on Miettinen \& Nurminen method.
PrimaryPercentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 48

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 48 are reported.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 48
Percentage of ParticipantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With an AE Leading to Discontinuation of Study Intervention at Week 480.52.2
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: -1.6 · 95% CI -4.9 to 0.2Difference in percentage versus (vs) Baseline ART was based on Miettinen \& Nurminen method.
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
Percentage of ParticipantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 4895.695.7
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: -0.08 · 95% CI -3.49 to 4.21Difference in percentage versus (vs) Baseline ART was based on Miettinen \& Nurminen method.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 48
Reported as:
Number · Percentage of Participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 48
Percentage of ParticipantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 4895.691.9
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: 3.75 · 95% CI -0.31 to 8.89Difference in percentage versus (vs) Baseline ART was based on Miettinen \& Nurminen method.
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryParticipants With HIV-1 RNA <200 Copies/mL at Week 144

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 96

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA ≥50 Copies/mL at Week 144

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

HIV-1 RNA levels in plasma were measured by a polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of \<50 copies/mL. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 is presented using the FDA Snapshot missing data approach.

Time frame:
Week 144

Results for this outcome have not been posted.

SecondaryMean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 48

Plasma CD4+ T-Cell Count was measured in cells/mm\^3 for baseline and 48 weeks. Baseline measurements were defined as the Day 1 value of each participant. The mean change of plasma CD4+ T-Cell count from baseline to Week 48 is presented.

Time frame:
Baseline at Day 1 and Week 48
Reported as:
Mean · cells/mm^3
Mean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 48
cells/mm^3Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Mean Change of Plasma Cluster of Differentiation 4 (CD4+) T-Cell Count From Baseline Day 1 to Week 485.41 (-12.11 to 22.94)18.22 (-11.84 to 48.28)
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: -15.43 · 95% CI -46.32 to 15.47Difference in percentage versus (vs) Baseline ART was based on a cDLA model.
SecondaryMean Change of Plasma CD4+ T-Cell Count From Baseline Week 48 to Week 96

Mean change from baseline at Week 48 in CD4+ T-cell count at Week 96. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.

Time frame:
Baseline at Week 48 and Week 96

Results for this outcome have not been posted.

SecondaryMean Change of Plasma CD4+ T-Cell Count From Baseline Day 48 to Week 144

Mean change from baseline at Week 48 in CD4+ T-cell count at Week 144. This outcome measure is applicable to participants who were randomized to switch to DOR/ISL at Week 48.

Time frame:
Baseline at Week 48 and Week 144

Results for this outcome have not been posted.

SecondaryMean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 96

Mean change from baseline at Day 1 in CD4+ T-cell count at Week 96. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.

Time frame:
Baseline at Day 1 and Week 96

Results for this outcome have not been posted.

SecondaryMean Change of Plasma CD4+ T-Cell Count From Baseline Day 1 to Week 144

Mean change from baseline at Day 1 in CD4+ T-cell count at Week 144. This outcome measure is applicable to those randomized to start DOR/ISL on Day 1.

Time frame:
Baseline at Day 1 and Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48

Participants with clinically significant confirmed viremia \[2 consecutive occurences 4 weeks (+-1 week) apart of HIV-1 RNA \>=200 copies/mL at any time during the study\] or who discontinue study intervention for another reason with HIV-1 RNA \>=200 copies/mL at the time of discontinuation met the criteria for post-baseline resistance testing. Participants with HIV-1 RNA \>=400 copies/mL or any participant for whom available genotypic or phenotypic data show evidence of resistance, irrespective of viral load were included in the resistance analysis subset. Plasma samples were collected for genotypic and phenotypic HIV-1 viral drug resistance testing and used to assess resistance-associated substitutions and virus susceptibility to study intervention. The percentage of participants in the resistance analysis subset with treatment-emergent resistance-associated substitutions to the study intervention is presented.

Time frame:
Up to Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 48
Percentage of participantsDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Percentage of Participants With Treatment-Emergent, Resistance-associated Substitutions at Week 480—
SecondaryMean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48

Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Low density lipoprotein cholesterol (LDL-C) at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Low Density Lipoprotein Cholesterol (LDL-C) at Week 48
mg/dLDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
PI-containing regimens (including PI- + InSTI-containing regimens)-7.10 (-27.06 to 12.86)-2.75 (-9.91 to 4.41)
non-PI- and non-InSTI-containing regimens5.07 (-0.77 to 10.91)0.29 (-5.92 to 6.50)
InSTI-containing regimens (non-PI-containing regimens)2.45 (-0.73 to 5.63)-0.37 (-5.02 to 4.28)
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · ANCOVA · p = 0.8340 · Estimated difference: -2.21 · 95% CI -24.91 to 20.49The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · ANCOVA · p = 0.4250 · Estimated difference: 3.44 · 95% CI -5.08 to 11.97The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · ANCOVA · p = 0.1618 · Estimated difference: 3.72 · 95% CI -1.50 to 8.95The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
SecondaryMean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48

Blood serum samples were taken at baseline and Week 48. The mean change from baseline in fasting Non-HDL-C at Week 48 is presented for PI-containing regimens (including PI- + InSTI-containing regimens), non-PI- and non-InSTI-containing regimens, and InSTI-containing regimens (non-PI-containing regimens) are presented.

Time frame:
Baseline and Week 48
Reported as:
Mean · mg/dL
Mean Change From Baseline in Fasting Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 48
mg/dLDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
PI-containing regimens (including PI- + InSTI-containing regimens)-11.80 (-32.04 to 8.44)-2.75 (-10.90 to 5.40)
non-PI- and non-InSTI-containing regimens5.78 (-0.40 to 11.97)0.44 (-6.47 to 7.35)
InSTI-containing regimens (non-PI-containing regimens)3.60 (0.06 to 7.14)3.29 (-5.87 to 12.44)
Statistical analysis
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: -7.02 · 95% CI -29.80 to 15.77The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: 3.99 · 95% CI -5.22 to 13.21The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
  • Doravirine/Islatravir (DOR/ISL) vs Baseline ART + DOR/ISL · Estimated difference: 1.02 · 95% CI -6.83 to 8.87The multiplicity adjusted 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline measurement and treatment.
SecondaryParticipants With One or More AEs at Week 96

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 96 is reported.

Time frame:
Up to Week 96

Results for this outcome have not been posted.

SecondaryParticipants With One or More AEs at Week 144

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Day 1 up to Week 144 is reported.

Time frame:
Up to Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 96

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 96 are reported.

Time frame:
Up to Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs Leading to Discontinuation of Study Intervention at Week 144

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Day 1 up to Week 144 are reported.

Time frame:
Up to Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With One or More AEs From Week 48 up to Week 96

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 96 is reported.

Time frame:
Week 48 up to Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With One or More AEs From Week 48 up to Week 144

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE from Week 48 up to Week 144 is presented.

Time frame:
Week 48 up to Week 144

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 96

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 96 are reported.

Time frame:
Week 48 up to Week 96

Results for this outcome have not been posted.

SecondaryPercentage of Participants With AEs Leading to Discontinuation of Study Intervention From Week 48 up to Week 144

An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experienced at least one AE leading to discontinuation of study intervention from Week 48 up to Week 144 are reported.

Time frame:
Week 48 up to Week 144

Results for this outcome have not been posted.

Adverse events

Collected over All-cause mortality and adverse events up to 48 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Doravirine/Islatravir (DOR/ISL)0/368 (0%)23/366 (6.3%)123/366 (33.6%)
Baseline ART + DOR/ISL1/185 (0.5%)9/185 (4.9%)73/185 (39.5%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
PneumoniaInfections and infestations3/3660/185
Atrial fibrillationCardiac disorders2/3660/185
AgranulocytosisBlood and lymphatic system disorders0/3661/185
Blood loss anaemiaBlood and lymphatic system disorders0/3661/185
CellulitisInfections and infestations0/3661/185
Viral upper respiratory tract infectionInfections and infestations0/3661/185
Ligament ruptureInjury, poisoning and procedural complications0/3661/185
Meniscus injuryInjury, poisoning and procedural complications0/3661/185
Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3661/185
Invasive breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3661/185
Most frequent other events
Most frequent other events
EventDoravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISL
Upper respiratory tract infectionInfections and infestations38/36625/185
DiarrhoeaGastrointestinal disorders29/3663/185
ArthralgiaMusculoskeletal and connective tissue disorders16/36614/185
HeadacheNervous system disorders19/36614/185
NasopharyngitisInfections and infestations20/36612/185
COVID-19Infections and infestations14/36610/185
Back painMusculoskeletal and connective tissue disorders18/36610/185

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISLTotal
Mean49.9 ± 12.649.5 ± 11.849.8 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISLTotal
Female15267219
Male216118334
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISLTotal
Hispanic or Latino542680
Not Hispanic or Latino310157467
Unknown or Not Reported426
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISLTotal
American Indian or Alaska Native101
Asian181028
Native Hawaiian or Other Pacific Islander112
Black or African American16684250
White14374217
More than one race381654
Unknown or Not Reported101
Baseline Antiretroviral (ART) Stratification at Randomization
Baseline Antiretroviral (ART) Stratification at Randomization(Count of Participants)Doravirine/Islatravir (DOR/ISL)Baseline ART + DOR/ISLTotal
PI-containing regimens (including PI- and InSTI-containing regimens)22830
InSTI-based regimens (non-PI containing regimens)233121354
All other non-PI- and non-InSTI containing regimens11156167
08

Study locations

53 sites
09

References and documents

Publications

  • Diamond TL, Grandhi A, Fuszard M, Xu Y, Nwoke U, Zhang Y, Klopfer SO, Eves K, Benner J, Li M, Greaves W, Lahoulou R, Kim J, Fox MC, Asante-Appiah E. Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA. J Infect Dis. 2026 May 29:jiag257. doi: 10.1093/infdis/jiag257. Online ahead of print. PubMed 42213454 ↗
  • Orkin C, Mngqibisa R, Velez JD, Kumar P, Braun DL, Carr A, Bloch M, Walmsley S, Tebas P, Yokomaku Y, Diamond TL, Jackson B, Eves K, Grandhi A, Fuszard M, Klopfer SO, Stamm LM, Fox MC, Kim J. Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial. Lancet. 2026 Feb 7;407(10528):599-610. doi: 10.1016/S0140-6736(25)01945-2. PubMed 41654374 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Oct 2024, 19 months.

Results were first posted in Nov 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 30, 2022
StartActual
Feb 20, 2023
Primary completionActual
Oct 10, 2024
CompletionEst.
Jul 11, 2028
Results first posted
Nov 21, 2025
Last update
Nov 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05631093
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Feb 20, 2023
Primary completion
Oct 10, 2024
Completion
Jul 11, 2028 (estimated)
Results posted
Nov 21, 2025
Last update
Nov 21, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion